Influence of CYP3A5 and ABCB1 polymorphisms on the pharmacokinetics of vincristine in adult patients receiving CHOP therapy.
Junichi NakagawaTakenori TakahataYu ChenKensuke SaitoKosuke KamataTakuto TachitaSatoru YamashitaKeigo SaitoKayo UenoAtsushi SatoHirotake SakurabaTakenori NiiokaPublished in: Cancer chemotherapy and pharmacology (2023)
The CYP3A5*3 polymorphism was found to be an indicator for predicting exposure to VCR in adult patients receiving CHOP therapy. This information may be useful for the individualization of VCR dosages.